Health‐related quality of life · people (of any age) with CSOM
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Ear pain (otalgia) or discomfort or local irritation · people (of any age) with CSOM
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hearing · people (of any age) with CSOM
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious complications · people (of any age) with CSOM
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Suspected ototoxicity · people (of any age) with CSOM
1 finding from 1 review
Resolution of ear discharge ‐ measured at 1 to 2 weeks · adults with CSOM
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Resolution of ear discharge ‐ measured after 4 weeks · adults with CSOM
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
FEV1 % predicted: relative change from baseline · adults and children with CF
1 finding from 1 review
Time to next exacerbation · adults and children with CF
1 finding from 1 review
Participants hospitalised for respiratory exacerbation · adults and children with CF
Summary of findings ‐ AZLI showed no clear difference in participants hospitalised for respiratory exacerbation compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events (AEs) (1 or more events) · adults and children with CF
Summary of findings ‐ AZLI showed no clear difference in any AEs compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality · adults and children with CF
Summary of findings ‐ AZLI showed no clear difference in mortality compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality maximum · newborns with late‐onset sepsis
It is very uncertain whether cefazolin plus amikacin changes all‐cause mortality maximum compared with vancomycin plus amikacin (very low certainty).
1 finding from 1 review
Serious adverse events maximum · newborns with late‐onset sepsis
It is very uncertain whether meropenem changes serious adverse events maximum compared with standard care (very low certainty).
1 finding from 1 review
Neurological developmental impairment maximum · newborns with late‐onset sepsis
It is very uncertain whether meropenem changes neurological developmental impairment maximum compared with standard care (very low certainty).
1 finding from 1 review
Necrotising enterocolitis maximum · newborns with late‐onset sepsis
It is very uncertain whether meropenem changes necrotising enterocolitis maximum compared with standard care (very low certainty).
1 finding from 1 review
All‐cause mortality maximum · newborns with late‐onset sepsis
It is very uncertain whether vancomycin plus gentamicin changes all‐cause mortality maximum compared with vancomycin plus aztreonam (very low certainty).
1 finding from 1 review
Serious adverse events maximum · newborns with late‐onset sepsis
It is very uncertain whether vancomycin plus gentamicin changes serious adverse events maximum compared with vancomycin plus aztreonam (very low certainty).
1 finding from 1 review
Necrotising enterocolitis maximum · newborns with late‐onset sepsis
It is very uncertain whether vancomycin plus gentamicin changes necrotising enterocolitis maximum compared with vancomycin plus aztreonam (very low certainty).
1 finding from 1 review
Serious adverse events maximum · newborns with late‐onset sepsis
It is very uncertain whether cefazolin plus amikacin changes serious adverse events maximum compared with vancomycin plus amikacin (very low certainty).
1 finding from 1 review